Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 3Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Pancreatic Neoplasms 1Metastatic Solid Tumors 1Malignant Solid Tumour 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × DOXO-EMCH × Clear all
NCT01706835 2022-02-10

Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡